JWBC
REGN icon

J.W. Burns & Co’s Regeneron Pharmaceuticals REGN Stock Holding History

J.W. Burns & Co’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,040
Closed -$660K – 189
2025
Q1 		$660K Hold
1,040
– – 0.09% 124
2024
Q4 		$741K Hold
1,040
– – 0.09% 119
2024
Q3 		$1.09M Hold
1,040
– – 0.14% 91
2024
Q2 		$1.09M Hold
1,040
– – 0.15% 92
2024
Q1 		$1M Buy
+1,040
New +$989K 0.14% 98

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

J.W. Burns & Co's REGN Position: Q2 2025 in Review

J.W. Burns & Co sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 1,040 shares — an estimated $660K sold.

J.W. Burns & Co first reported a position in REGN in Q1 2024 and held it in 5 quarters. The position peaked at $1.09M in Q3 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • J.W. Burns & Co reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • J.W. Burns & Co sold 1,040 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $660K.
  • J.W. Burns & Co first reported a position in Regeneron Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • J.W. Burns & Co's Regeneron Pharmaceuticals position peaked at $1.09M in Q3 2024.
  • 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on J.W. Burns & Co's 13F filing for Q2 2025, filed 10 Jul 2025.